AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19839170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 20
Study 17590966 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (both live and recorded)
Number of subjects: 19
Study 17590966 — intervention group
Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 19
Study 17590966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclassical music
Number of subjects: 19
Study 17590966 — intervention group
Group type: COMPARATOR
Intervention: Structured music therapy groups
Number of subjects: 19
Study 17590966 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive listening
Number of subjects: 19
Study 17590966 — intervention group
Group type: COMPARATOR
Intervention: Preferred music
Number of subjects: 19
Study 17590966 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-selected music
Number of subjects: 19
Study 11062578 — intervention group
Group type: EXPERIMENTAL
Intervention: Static splinting of extensor tendon repairs
Number of subjects: 33
Study 8617119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10mg per os four times a day for three days
Number of subjects: 14
Study 8617119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1595912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 49
Study 1595912 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 49
Study 6380179 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g of doxycycline preoperatively
Number of subjects: 102
Study 6380179 — intervention group
Group type: COMPARATOR
Intervention: 0.2 g of doxycycline preoperatively and 0.1 g of doxycycline on the first, second and third postoperative day
Number of subjects: 102
Study 29771270 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 30
Study 29771270 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitors (Control)
Number of subjects: 30
Study 28081952 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (1 mg, up to 12 doses, 8 h apart via extraventricular drain)
Number of subjects: 500
Study 28081952 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% saline, up to 12 doses, 8 h apart via extraventricular drain)
Number of subjects: 500
Study 28081952 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 500
Study 28081952 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 500
Study 26585569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive GMA (two sessions per week)
Number of subjects: 104
Study 26585569 — intervention group
Group type: COMPARATOR
Intervention: Weekly GMA (one session per week)
Number of subjects: 104
Study 23180876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 141
Study 23180876 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 141
Study 21594645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic disparity vergence modification with a test stimulus (4° step) and a conditioning stimulus (4° double step)
Number of subjects: 10
Study 21594645 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoria adaptation experiments measuring changes in phoria over a 5‐min period of sustained fixation
Number of subjects: 10
Study 19905889 — intervention group
Group type: EXPERIMENTAL
Intervention: DJBL
Number of subjects: 18
Study 19905889 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 18
Study 17033146 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 12639367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) plus tibolone (2.5 mg/day)
Number of subjects: 31
Study 12639367 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day) plus placebo
Number of subjects: 31
Study 10868555 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 60
Study 10868555 — intervention group
Group type: COMPARATOR
Intervention: 10 mg cetirizine
Number of subjects: 60
Study 9168290 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step: A Violence Prevention Curriculum
Number of subjects: 790
Study 9168290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 790
Study 1400054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Replacement (FR) - carbohydrate-electrolyte fluid replacement solution sufficient to replace 80 ± 2% of sweat loss
Number of subjects: 7
Study 1400054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Volume Expander (BVX) - 5.3 ml/kg of 6% dextran in saline
Number of subjects: 7
Study 1400054 — intervention group
Group type: COMPARATOR
Intervention: No Fluid (NF)
Number of subjects: 7
Study 2862419 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vitamin K administered at birth
Number of subjects: 0
Study 2862419 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no vitamin K administration)
Number of subjects: 0
Study 2862419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K administered to newborns with normotest levels < 30%
Number of subjects: 0
Study 29767650 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound
Number of subjects: 20
Study 29767650 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 20
Study 26865338 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior palatoplasty
Number of subjects: 62
Study 26865338 — intervention group
Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 62
Study 26865338 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful surgery
Number of subjects: 62
Study 26865338 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful surgery
Number of subjects: 62
Study 24742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Active psychosocial support intervention (4 interviews with a psychologist and consultation with a job retention physician)
Number of subjects: 0
Study 24742314 — intervention group
Group type: EXPERIMENTAL
Intervention: Active psychosocial support intervention
Number of subjects: 0
Study 24742314 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23215916 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory device (Pulsehaler(TM), Respinova Ltd)
Number of subjects: 22
Study 23215916 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory device
Number of subjects: 22
Study 23215916 — intervention group
Group type: COMPARATOR
Intervention: Control (muted sham device)
Number of subjects: 22
Study 23215916 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 20389176 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-liter PEG solution plus magnesium hydroxide
Number of subjects: 173
Study 20389176 — intervention group
Group type: COMPARATOR
Intervention: 4-liter PEG solution
Number of subjects: 173
Study 19277245 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 dietary supplementation (two 1000-mg capsules 3 times a day)
Number of subjects: 0
Study 19277245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17163325 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary precut approach (group B)
Number of subjects: 291
Study 17163325 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (group A)
Number of subjects: 291
Study 14624169 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 38
Study 14624169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C, 800 mg vitamin E, 10 mg folic acid
Number of subjects: 38
Study 14624169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10760722 — intervention group
Group type: EXPERIMENTAL
Intervention: IAN + IO injection with 1.8 mL of 1.5% etidocaine hydrochloride containing 1:200,000 epinephrine
Number of subjects: 48
Study 10760722 — intervention group
Group type: COMPARATOR
Intervention: IAN + mock IO injection
Number of subjects: 48
Study 10760722 — intervention group
Group type: EXPERIMENTAL
Intervention: IO injection of etidocaine hydrochloride
Number of subjects: 48
Study 8740982 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of reporting quality based on 21 principal parameters
Number of subjects: 102
Study 8740982 — intervention group
Group type: EXPERIMENTAL
Intervention: Study score of all investigations
Number of subjects: 102
Study 1728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin (4 x 1 gr intravenously during 24 h, perioperatively)
Number of subjects: 310
Study 1728756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 1728756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 310
Study 6469079 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose containing diet (LC diet) - 150 g/d, high protein (112 g/d)
Number of subjects: 40
Study 6469079 — intervention group
Group type: COMPARATOR
Intervention: Lactose free diet (LF diet) - normal protein (67 g/d)
Number of subjects: 40
Study 30758744 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ASA/200 mg paracetamol/50 mg caffeine (test)
Number of subjects: 18
Study 30758744 — intervention group
Group type: COMPARATOR
Intervention: 250 mg ASA/200 mg paracetamol (reference)
Number of subjects: 18
Study 28525958 — intervention group
Group type: EXPERIMENTAL
Intervention: Short thumb orthosis with MCP joint excluded
Number of subjects: 66
Study 28525958 — intervention group
Group type: COMPARATOR
Intervention: Short thumb orthosis with MCP joint included
Number of subjects: 66
Study 25427964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with a screwed tapered internal connection placed subcrestally (Group 1)
Number of subjects: 81
Study 25427964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with a screwed tapered internal connection placed crestally (Group 2)
Number of subjects: 81
Study 25427964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with an internal conical seal connection placed subcrestally (Group 3)
Number of subjects: 81
Study 25427964 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with an internal conical seal connection placed crestally (Group 4)
Number of subjects: 81
Study 24595113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using the two-diameter method
Number of subjects: 22
Study 24595113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using the free-tracing method
Number of subjects: 22
Study 21956192 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartNetCare‐HF (HNC)
Number of subjects: 715
Study 21956192 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 715
Study 19810099 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 1121
Study 17660031 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cutoff (HCO) intermittent hemodialysis (IHD) for 4 hours
Number of subjects: 10
Study 15957832 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Jiangtang tablet (QJT) 3 tabs, twice a day for 1 month
Number of subjects: 60
Study 15957832 — intervention group
Group type: COMPARATOR
Intervention: Glucophage 3 tabs, twice a day for 1 month
Number of subjects: 60
Study 15957832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (QJT and Glucophage)
Number of subjects: 60
Study 11867132 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper allocation concealment
Number of subjects: 0
Study 11867132 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 0
Study 11867132 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation concealment process
Number of subjects: 0
Study 10431273 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320 mgl/ml
Number of subjects: 110
Study 10431273 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate 320 mgl/ml
Number of subjects: 110
Study 10431273 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol
Number of subjects: 110
Study 10431273 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate
Number of subjects: 110
Study 10431273 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol and ioxaglate
Number of subjects: 110
Study 7589030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 1.0 g)
Number of subjects: 22
Study 7589030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (0.8 g)
Number of subjects: 22
Study 7589030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1.0 g)
Number of subjects: 22
Study 7589030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 22
Study 2209678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CYA) 5 mg/kg/day
Number of subjects: 31
Study 2209678 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/day
Number of subjects: 31
Study 7470854 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sentence processing
Number of subjects: 0
Study 7470854 — intervention group
Group type: COMPARATOR
Intervention: Repeated control presentations of a single word
Number of subjects: 0
Study 7470854 — intervention group
Group type: EXPERIMENTAL
Intervention: Last words in sentences
Number of subjects: 0
Study 7470854 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent change in typeface
Number of subjects: 0
Study 30700255 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablement program (4-10 weeks)
Number of subjects: 707
Study 30700255 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 707
Study 28181639 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of fall‐risk‐increasing‐drugs (FRIDs)
Number of subjects: 612
Study 28181639 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 612
Study 25319761 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A)
Number of subjects: 18
Study 25319761 — intervention group
Group type: COMPARATOR
Intervention: ethinyl estradiol (EE) 35 mcg/cyproterone acetate 2 mg (group B)
Number of subjects: 18
Study 23820059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg per day
Number of subjects: 276
Study 23820059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 21794858 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 0
Study 21794858 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance‐guided focused ultrasound
Number of subjects: 0
Study 19586937 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to dose-dense and high-dose chemotherapy (R-MegaCEOP14, R-MAD, BEAM) with autologous stem cell transplantation
Number of subjects: 94
Study 19586937 — intervention group
Group type: COMPARATOR
Intervention: High-dose chemotherapy without rituximab (MACOP-B, MAD, BEAM)
Number of subjects: 94
Study 17721968 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally intensive, contingency management treatment
Number of subjects: 118
Study 17721968 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive treatment
Number of subjects: 118
Study 14756849 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (2.5 mg or 5 mg based on migraine severity)
Number of subjects: 579
Study 14756849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 14756849 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 579
Study 11790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast of 10 or 50 g of carbohydrate (corn flakes)
Number of subjects: 150
Study 11790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack of 25 g of carbohydrate (corn flakes) after 1 1/2 h
Number of subjects: 150
Study 11790416 — intervention group
Group type: COMPARATOR
Intervention: Breakfast consumption
Number of subjects: 150
Study 11790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Midmorning snack after breakfast
Number of subjects: 150
Study 11790416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels
Number of subjects: 150
Study 9743320 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7978128 — intervention group
Group type: EXPERIMENTAL
Intervention: Three vital capacity breaths of room air during intravenous propofol administration (2.5 mg.kg‐1)
Number of subjects: 100
Study 7978128 — intervention group
Group type: COMPARATOR
Intervention: No specific instructions (control group)
Number of subjects: 100
Study 2688586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine hydrochloride
Number of subjects: 123
Study 2688586 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 123
Study 2688586 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment with nicardipine after placebo failure
Number of subjects: 123
Study 1081271 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2 g per day)
Number of subjects: 86
Study 1081271 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D2 (1000 IU calciferol per day)
Number of subjects: 86
Study 1081271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 31287199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (mechanical diagnosis therapy and transforaminal epidural steroid injections)
Number of subjects: 0
Study 31287199 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention while being on the waiting list)
Number of subjects: 0
Study 31287199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 31287199 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 31648781 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental antiplatelet treatment strategy
Number of subjects: 15991
Study 31648781 — intervention group
Group type: COMPARATOR
Intervention: Reference antiplatelet treatment strategy
Number of subjects: 15991
Study 31648781 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 15991
Study 26290343 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-mm Oxinium head on XLPE (Group C)
Number of subjects: 199
Study 26290343 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-mm Oxinium head on XLPE (Group D)
Number of subjects: 199
Study 26290343 — intervention group
Group type: COMPARATOR
Intervention: 28-mm ceramic head on CPE (Group A)
Number of subjects: 199
Study 26290343 — intervention group
Group type: COMPARATOR
Intervention: 28-mm ceramic head on XLPE (Group B)
Number of subjects: 199
Study 22712537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at three time points: 9 days prior to surgery, 1 month post-surgery, and 2 months post-surgery.
Number of subjects: 11
Study 22712537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ranibizumab).
Number of subjects: 11
Study 21297499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 60
Study 21297499 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 60
Study 19263591 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)
Number of subjects: 63
Study 19263591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17276974 — intervention group
Group type: EXPERIMENTAL
Intervention: Binasal cannula
Number of subjects: 60
Study 17276974 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 60
Study 15467494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60
Study 15467494 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study 11237808 — intervention group
Group type: EXPERIMENTAL
Intervention: No condom
Number of subjects: 42
Study 11237808 — intervention group
Group type: COMPARATOR
Intervention: Condom
Number of subjects: 42
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal general movements throughout
Number of subjects: 27
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient abnormal general movements
Number of subjects: 27
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent abnormal general movements
Number of subjects: 27
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Echodensities persisting beyond 14 days
Number of subjects: 27
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Echodensities up to 14 days
Number of subjects: 27
Study 9560043 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of quality of general movements
Number of subjects: 27
Study 7700070 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5‐5 mg daily for 6 months
Number of subjects: 23
Study 3662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of human growth hormone (hGH)
Number of subjects: 4
Study 3662594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile treatment with human growth hormone (hGH)
Number of subjects: 4
Study 3662594 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with human growth hormone (hGH)
Number of subjects: 4
Study 29691197 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention‐Medication Therapy Management (MI‐MTM)
Number of subjects: 46
Study 29691197 — intervention group
Group type: COMPARATOR
Intervention: Standard Medication Counseling (SMC)
Number of subjects: 46
Study 25757403 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Bias Modification (WMBM) task
Number of subjects: 60
Study 25757403 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 60
Study 23793946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 28
Study 23793946 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic calculator
Number of subjects: 28
Study 23793946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen and paper
Number of subjects: 28